In fiscal year 2025, DongKoo Bio & Pharma (006620) reported revenue of 242.7 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|
| 2025 | 242.7 billion KRW | 9.2 billion KRW | 50.2 billion KRW | [source] |
| 2024 | 249.3 billion KRW | 12.7 billion KRW | 2.0 billion KRW | [source] |
| 2023 | 215.7 billion KRW | 14.6 billion KRW | 11.8 billion KRW | [source] |
| 2022 | 195.0 billion KRW | 17.0 billion KRW | 6.6 billion KRW | [source] |
| 2021 | 155.1 billion KRW | 8.1 billion KRW | 9.3 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|
| 2025 | 330.0 billion KRW | 178.2 billion KRW | 151.8 billion KRW | [source] |
| 2024 | 241.9 billion KRW | 136.6 billion KRW | 105.3 billion KRW | [source] |
| 2023 | 190.3 billion KRW | 79.9 billion KRW | 110.4 billion KRW | [source] |
| 2022 | 171.0 billion KRW | 68.9 billion KRW | 102.1 billion KRW | [source] |
| 2021 | 153.9 billion KRW | 53.8 billion KRW | 100.1 billion KRW | [source] |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|
| 2025 | — | — | — | [source] |
| 2024 | 17.3 billion KRW | -45.0 billion KRW | 37.2 billion KRW | [source] |
| 2023 | 3.6 billion KRW | -5.1 billion KRW | 4.8 billion KRW | [source] |
| 2022 | 16.8 billion KRW | -27.0 billion KRW | 3.2 billion KRW | [source] |
| 2021 | 17.9 billion KRW | 464 million KRW | -3.7 billion KRW | [source] |
Cash flow figures for the relevant year were not collected.
